Literature DB >> 12750875

Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.

Davide Cervia1, Dominique Fehlmann, Daniel Hoyer.   

Abstract

Of the five cloned somatostatin (SRIF: somatotropin release inhibitory factor) receptors (sst1-5), only sst2 and sst5 receptors appear to be endogenously expressed and functionally active in AtT-20 mouse anterior pituitary tumour cells. In this study, the presence and the functional coupling of SRIF receptors to G-protein in AtT-20 cells was evaluated by receptor autoradiography and guanosine-5'-Omicron-(3-[35S]thio)-triphosphate ([35S]GTPgammaS) binding, respectively. In addition, transcriptional effects via the serum response element (SRE) were assessed in AtT-20-SRE-luci cells, engineered to express constitutively SRE upstream of the luciferase reporter gene. [125I]LTT-SRIF-28, [125I]CGP 23996 and [125I]Tyr3-octreotide binding illustrates the high level of sst2/5 receptor in AtT-20 cell membranes. SRIF-14 and SRIF-28 produced a concentration-dependent increase in [35S]GTPgammaS binding (pEC50=6.72 and 7.45; Emax=79 and 74.9, respectively) which was completely abolished by pertussis toxin. sst2/5 receptor-selective ligands caused a concentration-dependent increase in [35S]GTPgammaS binding (pEC50=7.74-5.84; Emax=76.6-20.2) while sst1/3/4 receptor-selective ligands were devoid of activity. The binding profiles of [125I]LTT-SRIF-28 and the inhibition of cAMP accumulation correlated highly significantly with their corresponding [35S]GTPgammaS binding profiles (r=0.862 and 0.874, respectively). The effects of the sst2 receptor-preferring agonists Tyr3-octreotide and BIM 23027 on [35S]GTPgammaS binding, but not those of SRIF-14 and the sst5/1 receptor selective-agonist L-817,818, were competitively antagonised by the sst2 receptor antagonist d-Tyr8-CYN 154806 (pKB=7.36 and 7.72, respectively; slope factors not significantly different from unity). In AtT-20-SRE-luci cells, which carry a SRE-luciferase construct functioning in a very efficient manner, SRIF and its analogues did not affect luciferase activity. Taken together, these results demonstrate that in AtT-20 cells the expression of sst2 and sst5 receptors fit with their functional coupling to G(i/o)-proteins. The pharmacological implications of the existence of different ligand/receptor complexes are discussed. However, the intracellular pathways coupled to the activation of sst2 and sst5 receptors appear not to modulate the SRE-mediated transcriptional activity, suggesting that SRIF effects on gene expression coupled to mechanisms that have promoters other than SRE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750875     DOI: 10.1007/s00210-003-0752-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  45 in total

1.  Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists.

Authors:  Caroline Nunn; Daniel Langenegger; Konstanze Hurth; Kerstin Schmidt; Dominique Fehlmann; Daniel Hoyer
Journal:  Eur J Pharmacol       Date:  2003-04-04       Impact factor: 4.432

2.  Characterisation of human recombinant somatostatin receptors. 4. Modulation of phospholipase C activity.

Authors:  S Siehler; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-11       Impact factor: 3.000

3.  Characterisation of human recombinant somatostatin receptors. 3. Modulation of adenylate cyclase activity.

Authors:  S Siehler; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-11       Impact factor: 3.000

4.  Interleukin-11 stimulates proopiomelanocortin gene expression and adrenocorticotropin secretion in corticotroph cells: evidence for a redundant cytokine network in the hypothalamo-pituitary-adrenal axis.

Authors:  C J Auernhammer; S Melmed
Journal:  Endocrinology       Date:  1999-04       Impact factor: 4.736

5.  Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.

Authors:  D Feuerbach; D Fehlmann; C Nunn; S Siehler; D Langenegger; R Bouhelal; K Seuwen; D Hoyer
Journal:  Neuropharmacology       Date:  2000-06-08       Impact factor: 5.250

6.  Biological activity of somatostatin receptors in GC rat tumour somatotrophs: evidence with sst1-sst5 receptor-selective nonpeptidyl agonists.

Authors:  D Cervia; P Zizzari; B Pavan; E Schuepbach; D Langenegger; D Hoyer; C Biondi; J Epelbaum; P Bagnoli
Journal:  Neuropharmacology       Date:  2003-04       Impact factor: 5.250

7.  Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression.

Authors:  G E Hardingham; S Chawla; C M Johnson; H Bading
Journal:  Nature       Date:  1997-01-16       Impact factor: 49.962

8.  Somatostatin inhibits potassium-evoked glutamate release by activation of the sst(2) somatostatin receptor in the mouse retina.

Authors:  Massimo Dal Monte; Cristina Petrucci; Andrea Cozzi; Jeremy P Allen; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-14       Impact factor: 3.000

9.  Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.

Authors:  L J Hofland; P M van Koetsveld; M Waaijers; J Zuyderwijk; W A Breeman; S W Lamberts
Journal:  Endocrinology       Date:  1995-09       Impact factor: 4.736

10.  Interleukin 1 induces beta-endorphin secretion via Fos and Jun in AtT-20 pituitary cells.

Authors:  M O Făgărăsan; F Aiello; K Muegge; S Durum; J Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

View more
  11 in total

Review 1.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 2.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

3.  Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.

Authors:  Thomas Günther; Michael Culler; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2016-03-11

Review 4.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

Review 5.  Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.

Authors:  Mehtap Cakir; Dorota Dworakowska; Ashley Grossman
Journal:  J Cell Mol Med       Date:  2010-11       Impact factor: 5.310

Review 6.  Current Evidence for a Role of Neuropeptides in the Regulation of Autophagy.

Authors:  Elisabetta Catalani; Clara De Palma; Cristiana Perrotta; Davide Cervia
Journal:  Biomed Res Int       Date:  2017-05-16       Impact factor: 3.411

7.  Dysfunctional autophagy induced by the pro-apoptotic natural compound climacostol in tumour cells.

Authors:  Silvia Zecchini; Francesca Proietti Serafini; Elisabetta Catalani; Matteo Giovarelli; Marco Coazzoli; Ilaria Di Renzo; Clara De Palma; Cristiana Perrotta; Emilio Clementi; Federico Buonanno; Claudio Ortenzi; Enrico Marcantoni; Anna Rita Taddei; Simona Picchietti; Anna Maria Fausto; Davide Cervia
Journal:  Cell Death Dis       Date:  2018-12-19       Impact factor: 8.469

8.  Bioactivity and Structural Properties of Novel Synthetic Analogues of the Protozoan Toxin Climacostol.

Authors:  Federico Buonanno; Elisabetta Catalani; Davide Cervia; Francesca Proietti Serafini; Simona Picchietti; Anna Maria Fausto; Simone Giorgi; Gabriele Lupidi; Federico Vittorio Rossi; Enrico Marcantoni; Dezemona Petrelli; Claudio Ortenzi
Journal:  Toxins (Basel)       Date:  2019-01-15       Impact factor: 4.546

9.  The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story.

Authors:  D Cervia; G Casini
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

10.  The Beta Adrenergic Receptor Blocker Propranolol Counteracts Retinal Dysfunction in a Mouse Model of Oxygen Induced Retinopathy: Restoring the Balance between Apoptosis and Autophagy.

Authors:  Maurizio Cammalleri; Filippo Locri; Elisabetta Catalani; Luca Filippi; Davide Cervia; Massimo Dal Monte; Paola Bagnoli
Journal:  Front Cell Neurosci       Date:  2017-12-12       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.